LAST 0.025
CHANGE 0.000
LAST: 0.025
CHANGE: 0.000
FSE: 18H
Download as PDF  

Annual General Meeting

Vancouver, British Columbia, August 2 2016 – PreveCeutical Medical Inc. ("PreveCeutical", or the "Company"), a health and wellness company focused on utilizing nature and science for the benefit of health conscious consumers, announces its first Annual General Meeting Monday August 8, 2016 at 13:00 PDT.

In addition to normal business, shareholders will be requested to consider the addition of two nominees to the Company’s Board, Greg S. Reid and Alex Bayer.

Greg S. Reid is one of the Top 10 speakers in the world as ranked by Forbes.com, is the Co-Founder of Secret Knock, again, ranked by Forbes.com as the second best gathering for entrepreneurs worldwide, a #1 best-selling author, entrepreneur and the CEO of several successful companies. Greg is one of the most sought-after keynote speakers in the corporate arena, universities and charitable organizations alike, sharing strategies for turning obstacles into opportunities. He has been published in more than 50 books, featured on nationally syndicated programs across the country, and he is the creator and producer for the internationally acclaimed films, Pass It On, Stickability and Three Feet from Gold. Currently residing in San Diego, California, Greg has more than 20 years experience in sales and marketing, he mentors youth in the San Diego area on positive thinking and achieving their dreams, and he has dedicated his life to helping others achieve the ultimate fulfillment in life by finding and living a life of purpose.

Alex Bayer is the Principal of Bayer Law Corporation, a Vancouver-based consulting company providing legal services to public and private companies. He has more than 10 years’ experience advising public companies on issues relating to corporate governance, securities law and continuous disclosure compliance. Alex also sits on the board of Azarga Uranium Corporation a resource company listed on the Toronto Stock Exchange where he is the Chair of the Disclosure Committee and member of the Audit Committee.

“Greg has been incredibly valuable to date. He’s opened doors for the Company that will accelerate our growth and he’s already introduced key industry leaders that will help bring existing and new products to market.” said Stephen Van Deventer, Chairman and CEO at PreveCeutical. “Also we’re very excited to include Alex as a nominee to the Board as he brings more than 10 years’ legal, business and transaction experience that rounds-out an already strong team.”

About PreveCeutical

For more information about PreveCeutical, please visit www.preveceutical.com, follow us on Twitter: https://twitter.com/preveceuticals, or on Facebook: www.facebook.com/Preveceutical

On Behalf of the Board,

"Stephen Van Deventer"
Chairman & CEO

This news release may contain forward-looking statements, including without limitation, future operations of PreveCeutical Medical Inc. (the "Company"). Forward-looking statements address future events and conditions and therefore involve inherent risks, uncertainties and assumptions. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as “may”, “expect”, “estimate”, “will”, “anticipate”, “intend”, “believe” and “continue” or the negative thereof or similar variations. Actual results may differ materially from those currently anticipated in such statements and the Company undertakes no obligation to update such statements, except as required by law. While such estimates and assumptions are considered reasonable by the management of the Company, they are inherently subject to significant business, economic, competitive and regulatory uncertainties and risks. In particular, there is no guarantee that the Blue Scorpion Venom will effectively treat or cure cancer or other diseases. Accordingly actual results may differ materially from those currently anticipated in such statements.

The Company has made numerous assumptions regarding, among other things: the effectiveness of its products; the demand for its products and the stability of economic and market conditions. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including: that the Company may lose or abandon or may fail to receive necessary licenses and permits; labour disputes; the Company may not receive the necessary regulatory approvals for its products; the increase in cost estimates and the potential for unexpected costs and expenses; general economic and market conditions may worsen; market shifts may require a change in strategic focus; the Company may not be able to raise additional funds when necessary; litigation; and competition. Factors that could cause actual results to differ materially from those in forward looking statements include continued availability of capital and financing and general economic, market or business conditions, consumer sentiment towards the Company’s products, competition, the failure of counterparties to perform their contractual obligations, and fees charged by service providers.

All forward-looking statements concerning the Company's future plans and operations, including management's assessment of the Company's operational expectations or beliefs may be subject to certain assumptions, risks and uncertainties beyond the Company's control. Investors are cautioned that any such statements are not guarantees of future performance and that actual performance and financial results may differ materially from any estimates or projections. Accordingly, readers should not place undue reliance on forward-looking statements and information, which are qualified in their entirety by this cautionary statement. There can be no assurance that forward-looking information, or the material factors or assumptions used to develop such forward looking information, will prove to be accurate.

PreveCeutical Medical Inc.
Suite 605 – 815 Hornby Street,
Vancouver, B.C., V6Z 2E6, Canada

Sign up for the latest news and updates